Drug Trial Radar · NCT05439824
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
Last checked: Nov 19, 2026Latest source record: May 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
450
Actual
Start
Jun 28, 2022
Primary completion
Jan 12, 2023
Study completion Jun 28, 2023
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006)in healthy participants aged 18 or more.
Conditions
- SARS-CoV-2 Infection
Interventions
SYS6006 20 μgBiological
SARS-CoV-2 mRNA Vaccine
SYS6006 30 μgBiological
SARS-CoV-2 mRNA Vaccine
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibodyTime frame: 14 days after the second dose
- Adverse events (AEs), including solicited AEs and unsolicited AEsTime frame: From the first dose through 30 days following the second dose
- AEs associated with the study interventionTime frame: From the first dose through 30 days following the second dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hebei Provincial Center For Disease Control and Prevention
Shijiazhuang, Hebei, China
Sir Run Run Hosipital Nanjing Medical University
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.